Orion Presenting at Bio-Europe Spring
Orion Biotechnology will be presenting at this year’s Bio-Europe Spring edition, to be held March 22-25. Given the continuing Pandemic, the conference will follow a fully digital front making it
Precision Engineering GPCR-Targeted Therapeutics
Orion Biotechnology is a clinical stage biotechnology company discovering and developing next-generation G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of cancer and other serious diseases.
A Break Through Science & Technology Platform
We precision-engineer natural peptide and protein analogs that bind to GPCR targets with both enhanced potency and tailored signaling activity. This novel scientific approach is enabled by Orion’s proprietary drug discovery platform and has produced a growing pipeline of drug candidates that effectively target GPCRs implicated across therapeutic areas of high unmet need.
CCR5 Inhibitor Program
Orion’s lead compound, OB-002, is a chemokine analog of CCL5 with best-in-class potency and a proven mechanism of action shown to have broad applicability across a range of serious diseases, including Cancer, Neuroinflammation and HIV.
Recognized
Leadership
Previous
Next
Orion presented the Results of our Successful Phase 1 Clinical Trial at the HIV Research for Prevention Conference
January 29, 2021
Ottawa, Canada January 27, 2021: Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that they will be presenting the results of
Orion Biotechnology Project Awarded Grant to Advance Drug Discovery
January 14, 2021
Genève SWITZERLAND, Jan 14, 2021 (GLOBE NEWSWIRE) — Orion Biotechnology Holding SA., a biotechnology company focused on precision engineering small protein therapeutics, today announced that its drug discovery project was
Therapeutic Developed using Novel Approach to Drug Discovery has Successfully Completed Phase 1 Clinical Trial
October 16, 2020
OTTAWA, Canada, Oct. 15, 2020 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering GPCR-targeted therapeutics, today announced the results of their Phase 1
Global Headquarters
343 Preston Street
11th floor,
Ottawa, On K1S 1N4
CANADA
+1 343.291.1032
Switzerland
Campus Biotech
Innovation Park
Avenue de Sécheron 15
1202 Genève
SWITZERLAND
Poland
Orion Biotechnology
Life Science Park
UI Bobrzyńskiego 14
30-348 Krakôw
POLAND
